Pancreatic Cancer Research

ResearcherUniversité Libre de BruxellesActive in the last 2 years

Pieter Demetter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7981-4645; OpenAlex author ID A5085079548. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 2 papers · 2014: none · 2015: 3 papers · 2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 18

  1. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy. Co-author DOI 10.1038/s41416-025-03274-0↗
  2. Glycation Stress–Driven Transcriptomic Signature Predicts Survival Benefit from Adjuvant Gemcitabine in Resectable Pancreatic Cancer Co-author DOI 10.1101/2025.07.07.663493↗
  3. Impact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study. Co-author DOI 10.1093/bjsopen/zrae134↗
  4. Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after Total Neoadjuvant Therapy including Stereotactic Body Radiotherapy Co-author DOI 10.1101/2024.04.30.591890↗
  5. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline rese… Co-author DOI 10.1186/s12885-023-11327-x↗
  6. Pancreatic Cancer Meets Human Microbiota: Close Encounters of the Third Kind. Co-author DOI 10.3390/cancers13061231↗
  7. DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer. Co-author DOI 10.1038/bjc.2016.319↗
  8. Feasibility of Immunohistochemistry on Endoscopic Ultrasound Fine-Needle Aspiration Samples for Evaluating Predictive Biomarkers in Pancreatic Cancer Managemen… First author DOI 10.1097/mpa.0000000000000672↗
  9. Asparagine Synthetase Expression and Phase I Study With L-Asparaginase Encapsulated in Red Blood Cells in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000394↗
  10. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. Last author DOI 10.1111/his.12577↗
  11. Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-0667↗
  12. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejca.2013.04.017↗
  13. Pancreatic adenocarcinoma: general histological overview. Co-author DOI 10.1080/00015458.2013.11680891↗
  14. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Co-author DOI 10.1053/j.gastro.2012.06.006↗
  15. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  16. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdr617↗
  17. Molecular changes in pancreatic cancer: implications for molecular targeting therapy. Co-author PMID 22870784↗
  18. Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P8… Co-author DOI 10.1667/rr2068.1↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Luc Van Laethem · 13 shared papers, 2012–2026 · strength 1.18
  2. Christelle Bouchart · 6 shared papers, 2021–2026 · strength 1.09
  3. Julie Navez · 5 shared papers, 2023–2026 · strength 0.95
  4. Tatjana Arsenijevic · 5 shared papers, 2021–2026 · strength 0.92
  5. Oier Azurmendi Senar · 4 shared papers, 2024–2026 · strength 0.77
  6. Nicky D’Haene · 5 shared papers, 2013–2026 · strength 0.77
  7. Jean‐Baptiste Bachet · 12 shared papers, 2012–2026 · strength 0.76
  8. Rémy Nicolle · 4 shared papers, 2021–2026 · strength 0.73
  9. Kosta Stosic · 3 shared papers, 2024–2026 · strength 0.58
  10. Jean Closset · 5 shared papers, 2012–2024 · strength 0.44
  11. Raphaël Maréchal · 10 shared papers, 2012–2016 · strength 0.38
  12. Léo Mas · 2 shared papers, 2024–2026 · strength 0.38
  13. Shulin Zhao · 2 shared papers, 2024–2026 · strength 0.38
  14. Matthieu Hein · 2 shared papers, 2024–2026 · strength 0.38
  15. Ilse Rooman · 2 shared papers, 2024–2026 · strength 0.38
  16. Jerome F. Cros · 5 shared papers, 2013–2025 · strength 0.37
  17. Francesco Puleo · 4 shared papers, 2015–2021 · strength 0.30
  18. Jacques M.E. Deviere · 3 shared papers, 2012–2024 · strength 0.27
  19. Thierry Conroy · 2 shared papers, 2012–2025 · strength 0.22
  20. Ellis Michiels · 1 shared paper, 2026 · strength 0.22
  21. Magali Svrcek · 6 shared papers, 2012–2015 · strength 0.21
  22. Jean-Luc Van-Laethem · 1 shared paper, 2025 · strength 0.20
  23. Akeila Bellahcène · 1 shared paper, 2025 · strength 0.20
  24. Rebekah Crake · 1 shared paper, 2025 · strength 0.20
  25. Maria Antonietta Bali · 1 shared paper, 2024 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.